<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pharmacol Clin Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">J Pharmacol Clin Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of pharmacology &amp; clinical toxicology</journal-title></journal-title-group><issn pub-type="epub">2333-7079</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11671133</article-id><article-id pub-id-type="pmcid-ver">PMC11671133.1</article-id><article-id pub-id-type="pmcaid">11671133</article-id><article-id pub-id-type="pmcaiid">11671133</article-id><article-id pub-id-type="manuscript-id">NIHMS2040870</article-id><article-id pub-id-type="pmid">39726772</article-id><article-id pub-id-type="doi">10.47739/pharmacology1184</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2040870</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2040870</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule-1 Biomarker</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Thompson</surname><given-names initials="LE">Lauren E.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghimire</surname><given-names initials="A">Avisek</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wen</surname><given-names initials="X">Xia</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="C">Christine</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Choza</surname><given-names initials="J">Juliana</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Doherty</surname><given-names initials="CL">Cathleen L.</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buckley</surname><given-names initials="BT">Brian T.</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bowles</surname><given-names initials="DW">Daniel W.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>O&#8217;Bryant</surname><given-names initials="CL">Cindy L.</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pfister</surname><given-names initials="DG">David G.</given-names></name><xref rid="A8" ref-type="aff">8</xref><xref rid="A10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jaimes</surname><given-names initials="EA">Edgar A.</given-names></name><xref rid="A9" ref-type="aff">9</xref><xref rid="A10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aleksunes</surname><given-names initials="LM">Lauren M.</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Joy</surname><given-names initials="MS">Melanie S.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA</aff><aff id="A2"><label>2</label>Cancer Center, University of Colorado Anschutz Medical Campus, USA</aff><aff id="A3"><label>3</label>Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, USA</aff><aff id="A4"><label>4</label>Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, USA</aff><aff id="A5"><label>5</label>Environmental and Occupational Health Sciences Institute, Rutgers University, USA</aff><aff id="A6"><label>6</label>Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, USA</aff><aff id="A7"><label>7</label>Department of Earth and Planetary Sciences, Rutgers University, USA</aff><aff id="A8"><label>8</label>Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center, USA</aff><aff id="A9"><label>9</label>Renal Service, Memorial Sloan Kettering Cancer Center, USA</aff><aff id="A10"><label>10</label>Department of Medicine, Weill Cornell Medical College, USA</aff><author-notes><corresp id="CR1"><label>*</label><bold>Corresponding author</bold>: Melanie S. Joy, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, 12850 E. Montview Blvd, Mail Stop C238, Room V20-4108, Aurora, CO 80045</corresp><fn fn-type="COI-statement" id="FN1"><p id="P64">CONFLICT OF INTEREST</p><p id="P65">The authors declare no conflicts of interest. Lauren M. Aleksunes is a member of the scientific advisory board of RenaSym<sup>&#174;</sup> Simulations Plus.</p></fn></author-notes><pub-date pub-type="ppub"><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>9</month><year>2024</year></pub-date><volume>12</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">477713</issue-id><elocation-id>1184</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>10</day><month>12</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>26</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>26</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-28 23:25:14.587"><day>28</day><month>12</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2040870.pdf"/><abstract id="ABS1"><p id="P1">Cisplatin is a platinum-based chemotherapeutic that causes acute kidney injury in over 30% of patients. The aim of this study was to develop a population pharmacokinetic/toxicodynamic (PKTD) model of cisplatin-induced kidney injury that incorporated plasma total platinum and urinary kidney injury molecule-1 (KIM-1) concentrations. Cancer patients receiving their first or second round of cisplatin-containing chemotherapy (n=39) were prospectively randomized to a 5-HT<sub>3</sub> antagonist (5-HT<sub>3</sub>A) antiemetic (ondansetron, granisetron, or palonosetron) and had blood and urine collected over 10 days. Plasma concentrations of total platinum and urinary concentrations of KIM-1 were used in the development of a nonlinear mixed effect population PKTD model using Phoenix<sup>&#174;</sup> NLME (v8.3, Certara Inc.). A stepwise search was used to test potential covariates that influenced PKTD parameters. A two-compartment model best described the plasma total platinum concentration vs. time data and was expanded to an effect compartment PKTD model incorporating urinary KIM-1 concentrations. Significant covariate effects for the PKTD model included previous cisplatin exposure on the volume of the central compartment (V1), 5-HT<sub>3</sub>A antiemetic treatment on the volume of the peripheral compartment (V2), and baseline urinary KIM-1 levels on the maximum effect (Emax) parameter. The model demonstrated that ondansetron-treated subjects had a 163% increase in exposure to plasma total platinum, a 94% increase in urinary KIM-1 maximum concentrations, and a 235% increase in total urinary KIM-1 excretion compared to palonosetron-treated subjects, suggesting that palonosetron may be a preferred 5-HT<sub>3</sub>A to reduce the risk of cisplatin-induced kidney injury.</p></abstract><kwd-group><kwd>Cisplatin</kwd><kwd>Pharmacokinetics</kwd><kwd>Toxicodynamics</kwd><kwd>Pharmacodynamics</kwd><kwd>Nephrotoxicity</kwd><kwd>Kidney Injury</kwd><kwd>5-HT<sub>3</sub> Antagonist</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>